John-Arne Røttingen
@jarottingen.bsky.social
320 followers 4 following 2 posts

Chief Executive Officer (CEO) at Wellcome

John-Arne Røttingen is a Norwegian medical scientist, research administrator and civil servant. He is currently the Chief Executive Officer of the Wellcome Trust. Previously, he served as Ambassador for Global Health in the Norwegian Ministry of Foreign Affairs, and has been a special advisor to the World Health Organization (WHO). .. more

Economics 36%
Public Health 18%
Posts Media Videos Starter Packs

wellcometrust.bsky.social
Hello to everyone on Bluesky 👋

We’re a global charitable foundation. We believe science and research are essential to solving the world’s health challenges – and everyone should benefit from them.

Find out more about us ⤵️
wellcome.org/what-we-do?u...
What we do | Wellcome
Wellcome improves health for everyone by funding research, leading policy and advocacy campaigns, and building global partnerships.
wellcome.org

jarottingen.bsky.social
Superb to see so many recognised in science and public health in the King's birthday honours. Congratulations in particular to former @wellcometrust.bsky.social director of infectious disease Gordon Dougan and @lshtm.bsky.social director Liam Smeeth.

aidanwarner.bsky.social
Spending review research commitments are "a reduction in ambition at a time when the UK desperately needs the economic growth that investing in science brings" Wellcome ceo @jarottingen.bsky.social says
John-Arne Røttingen, chief executive of Wellcome, the UK's largest non-governmental funder of research, said:
 
“The previous government planned to reach £22bn a year of R&D spending last year, then pushed it back. Today's review pushes that aim back further to 2030. This is a reduction in ambition at a time when the UK desperately needs the economic growth that investing in science brings.
 
“The squeeze on the health research budget in particular risks limiting our ability to find new treatments and innovation in the NHS. Britain has a strength in life sciences and medicine that it should be leaning into, to benefit patients and the economy.
 
“Meanwhile, a consequence of the disappointing decision to cut overseas aid is that the science it funds, tackling some of the world’s biggest health threats, will be halved by the end of the decade."